## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($774.60)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Sands Capital Management LLC Buys 54,117 Shares of McKesson Corporation $MCK**
- Source: MarketBeat | 20251204T131001 | Bullish | Relevance: 100%
- Sands Capital Management LLC significantly increased its stake in McKesson Corporation, purchasing 54,117 additional shares, bringing its total to 145,867 shares valued at approximately $106.9 million. Other major institutions like Norges Bank, Nuveen, Arrowstreet, Wellington, and Boston Partners also accumulated substantial positions, indicating strong institutional confidence in McKesson. The company recently reported better-than-expected earnings, declared a quarterly dividend, and holds a "Moderate Buy" consensus rating from analysts with an $887.69 price target.

**2. McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025**
- Source: ts2.tech | 20251203T230808 | Bullish | Relevance: 100%
- McKesson Corporation (MCK) experienced a stock price drop of nearly 3% on December 3, 2025, closing at $805.37, despite being a strong performer in U.S. healthcare throughout the year. The pullback is attributed to profit-taking, institutional portfolio adjustments, and investors processing new guidance and oncology initiatives. The company is actively reshaping its portfolio by spinning off its Medical-Surgical Solutions segment and focusing on oncology, specialty drugs, and tech-enabled services, with analysts generally bullish on its long-term prospects.

**3. McKesson Corporation pushes for biopharma collaboration in cancer care**
- Source: Traders Union | 20251203T025213 | Bullish | Relevance: 100%
- McKesson Corporation advocates for increased collaboration within the biopharma industry to enhance cancer care. The company emphasizes the necessity for biopharma companies to partner with community oncologists to support policies that protect access and foster innovation in the medical field amidst rapid policy changes.

**4. Invesco Ltd. Has $689.33 Million Stock Position in McKesson Corporation $MCK**
- Source: MarketBeat | 20251204T120834 | Somewhat-Bullish | Relevance: 100%
- Invesco Ltd. reduced its stake in McKesson Corporation by 11.4% in Q2, now holding 940,708 shares valued at $689.33 million, though institutional ownership remains high at 85.07%. Analysts maintain a "Moderate Buy" rating with a consensus target price of $887.69, following positive Q3 earnings where McKesson beat estimates with $9.86 EPS. The company also declared a quarterly dividend of $0.82, and insider selling activity was noted with the CAO reducing their shares by 50.08%.

**5. Brandes Investment Partners LP Sells 151,828 Shares of McKesson Corporation $MCK**
- Source: MarketBeat | 20251203T050841 | Somewhat-Bullish | Relevance: 100%
- Brandes Investment Partners LP significantly reduced its stake in McKesson Corporation, selling 151,828 shares and retaining 177,220 shares valued at approximately $129.9 million. This comes after McKesson reported strong Q3 earnings, beating EPS expectations but slightly missing revenue estimates, and announced a quarterly dividend of $0.82. Several other institutional investors also adjusted their positions in MCK, while analysts have maintained a "Moderate Buy" rating with an average price target of $887.69.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Wells Fargo | $914 | $816 | +12% |
| 2025-11-06 | UBS | $980 | $920 | +7% |
| 2025-11-06 | Baird | $927 | $873 | +6% |
| 2025-11-06 | Morgan Stanley | $916 | $857 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Wells Fargo | main | Equal-Weight |
| 2025-11-06 | UBS | main | Buy |
| 2025-11-06 | Baird | main | Outperform |
| 2025-11-06 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-5.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Analyst sentiment positive (4 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $103.0B |
| Beta | 0.38 |
| 52W Range | $565.75 - $895.58 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 18.6 |
| Current P/E | 21.1 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.9% to -6.6% (-5.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.6pp (needs >3.0% for momentum thesis). Underperforming sector by 5.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-9.31), momentum weakening. RSI neutral at 42. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.59% (CS: 2) | Weak |
| RSI_14 | 42.5 | Neutral |
| MACD Histogram | -9.31 | Bearish |
| vs SMA20 | 0.954x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $814.18
- **Stop Loss:** $774.60 (4.9% risk)
- **Target:** $853.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $9,770.16
- **Portfolio %:** 9.77%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*